Christopher Loose
Equibles does not estimate personal net worth.
Get an email with a short summary when Korro Bio, Inc. publishes a filing, an earnings call transcript or a press release.
Get KRRO alertsAbout Christopher Loose
Christopher Loose is recorded as CEO at Korro Bio, Inc. (KRRO) since February 11, 2023. Korro Bio, Inc. reported in an 8-K filed July 31, 2023 that Christopher Loose resigned as Chief Scientific Officer, effective July 28, 2023. Korro Bio, Inc. reported in an 8-K filed February 13, 2023 that Christopher Loose was appointed Interim Chief Executive Officer, effective February 11, 2023. The proxy statement of Korro Bio, Inc. reports total compensation of $2,894,515 for Christopher Loose in fiscal 2019, including a base salary of $379,167. Disclosed compensation is on record for 2 fiscal years. Korro Bio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Korro Bio, Inc. includes David L. Lucchino (CEO and Board Member), Ram Aiyar (CEO, CFO and Board Member), Nessan Bermingham (Chairman and Board Member) and 7 others.
“On July 28, 2023, Christopher Loose, Ph.D., notified Frequency Therapeutics, Inc. (the "Company") that he would be resigning from his position as Chief Scientific Officer of the Company, effective July 28, 2023 (the "Separation Date").”
“On February 11, 2023, the Company’s Board of Directors appointed Christopher Loose, Ph.D., as Interim Chief Executive Officer while David Lucchino, the Company’s President and Chief Executive Officer, is on a temporary medical leave of absence after being hospitalized with bacterial meningitis.”
Affiliation history
-
Current
2023-02-11–present
Company network
Leadership on record at Korro Bio, Inc.
- David L. Lucchino CEO, Board Member
- Ram Aiyar CEO, CFO, Board Member
- Nessan Bermingham Chairman, Board Member
- Peter P. Pfreundschuh CFO
- Richard M. Mitrano CFO, Chief Accounting Officer
- Vineet Agarwal CFO
- Todd Chappell COO
- Steve Colletti CTO
- Jeffrey Cerio General Counsel
- Michael D. Bookman General Counsel
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Korro Bio, Inc. (KRRO) | Chief Scientific Officer | $379,167 | $2,894,515 |
| 2018 | Korro Bio, Inc. (KRRO) | Chief Scientific Officer | $316,325 | $578,134 |